This page is general health information, not medical advice. It cannot tell you whether you have an infection. A clinician can, and the testing options on this site are a good place to start.

Mycoplasma genitalium is a sexually transmitted bacterium that many people have never heard of. It rarely shows up on a standard STI panel, and that surprises people. This guide explains what it is, what the research suggests about it, and how to ask about testing in Atlanta.

One note on format. This topic is an organism, not an ingredient. So the usual sections on composition, research, safety and quality are covered here as biology, research findings, safety of testing and treatment, and how to judge a testing option.

What mycoplasma genitalium is

Mycoplasma genitalium (often shortened to M. genitalium or MG) is a bacterium that infects the urinary and genital tracts. The CDC STI Treatment Guidelines (2021) describe it as a cause of urethritis, which is inflammation of the urethra. The guidelines also link it to cervicitis and pelvic inflammatory disease.

It is spread through sexual contact. It can affect people of any gender or orientation. Having it says nothing about a person's character or choices.

Biology and key features

This is the closest thing to a "composition" section. M. genitalium is one of the smallest known bacteria that can reproduce on its own. Research suggests two features matter most for patients.

It has no cell wall. Some antibiotics work by attacking the bacterial cell wall. Research suggests those medicines are not a good fit for this organism. That is one reason a clinician chooses treatment carefully.
It is slow and hard to grow. It does not grow easily in a standard lab culture. The CDC describes testing by nucleic acid amplification tests (NAATs), which look for the bacterium's genetic material.

It is also a different organism from the bacteria behind chlamydia. The symptoms can look similar, so a test is the only way to tell them apart.

Mycoplasma genitalium symptoms

Many people with M. genitalium have no symptoms at all. When symptoms do appear, the CDC and other public health sources describe patterns that overlap with other infections.

In people with a penis

Burning or discomfort when urinating
Discharge from the penis
Urethritis that returns or does not go away after treatment for another infection

In people with a cervix

Unusual vaginal discharge
Bleeding between periods or after sex
Pain during sex
Lower abdominal or pelvic pain, which can signal pelvic inflammatory disease

None of these symptoms point to one cause. Chlamydia, gonorrhea, trichomoniasis and non-infectious problems can look the same. Only a clinician and a test can tell what is going on.

When CDC recommends testing

Testing for M. genitalium is not routine. The CDC STI Treatment Guidelines (2021) recommend considering it in specific situations:

Persistent or recurrent urethritis. This means symptoms that continue or come back after treatment for the more common causes.
Persistent or recurrent cervicitis. This is the same pattern in people with a cervix.
Pelvic inflammatory disease. The CDC says testing can be considered for people with this diagnosis.
Partners of someone with a confirmed infection. The CDC says partners can be evaluated and offered testing.

The CDC does not recommend screening people who have no symptoms and no known exposure. That is a key reason you may not see it offered at a general screening visit.

The CDC does not publish a window period for M. genitalium, so no number is given here. A clinician can advise on timing based on your situation.

Why it is not on standard panels

Most low-cost screening panels cover chlamydia, gonorrhea, syphilis and HIV. M. genitalium is usually left off for a few reasons.

The CDC does not recommend routine screening of people without symptoms.
Testing needs a NAAT that is designed for this organism. The CDC notes that availability varies by lab.
Treatment is complicated by antibiotic resistance, so finding it without a clear reason can lead to treatment that does not help.

If you have had symptoms that did not clear up, the right move is to tell the clinician that. Ask whether M. genitalium testing makes sense for you.

Research findings, and what they do and do not show

Research on M. genitalium keeps growing. Here is what the CDC STI Treatment Guidelines (2021) and the studies they review suggest. These are observations, not settled answers.

Antibiotic resistance is a major concern. Research suggests that resistance to a commonly used antibiotic class (the macrolides) is widespread. Resistance to another class (the fluoroquinolones) has also been reported.
Resistance changes the plan. The CDC says resistance testing, where it is available, can guide which medicines a clinician chooses. This is sometimes called resistance-guided treatment.
Links to reproductive health are still being studied. Research suggests an association with pelvic inflammatory disease and with cervicitis. How often it leads to longer-term problems is not fully known.
Symptoms do not match infection neatly. Studies suggest many infections cause no symptoms, which is part of why screening is not recommended.

Safety profile of testing and treatment

A test for M. genitalium is typically a urine sample or a swab. The CDC describes NAATs as the recommended method. Testing itself carries little risk.

Treatment is a different matter and belongs with a clinician. The CDC says M. genitalium is curable with antibiotics, but the choice depends on resistance results, other infections and your health history. Your clinician decides which medicines to prescribe. Do not use leftover antibiotics or medicine from someone else.

Things to raise with a clinician before treatment:

Any allergies to antibiotics
Pregnancy or plans to become pregnant
Other medicines or supplements you take
Liver or kidney conditions

After treatment, the CDC says to follow your clinician's advice about avoiding sex until treatment is complete and symptoms have resolved. Partners may also need evaluation, so reinfection does not happen.

Georgia's clinicians report chlamydia, gonorrhea, syphilis and HIV to public health under the Georgia Department of Public Health notifiable condition rules. The reporting list in this guide's sources does not include M. genitalium. Ask your clinic what applies to your visit.

Atlanta context

Persistent urethritis is often traced to a more common infection first, so local numbers help explain why clinicians start there. The Georgia DPH OASIS data tool reports 10,599 chlamydia cases in Fulton County in 2023, a rate of 978.7 per 100,000 people. It reports 6,167 gonorrhea cases in Fulton County that year, a rate of 569.4 per 100,000. DeKalb County, which covers part of Atlanta, had a chlamydia rate of 854.9 and a gonorrhea rate of 430.8 per 100,000.

Those numbers describe how common the usual causes are. They say nothing about any one person. For a full picture of options, see our guide to STD testing in Atlanta and what it costs.

Where to ask about testing in Atlanta

Here is the honest limit: none of the Atlanta clinics' published pages say they run an M. genitalium test. So the practical step is to call and ask. The list below shows what each clinic publishes about its services. You can also browse the local testing list.

Clinic	What it publishes	Phone
10 Park Place Health Center (Fulton County Board of Health), 10 Park Place S.E., 5th floor	STI screening and treatment on a sliding fee scale. Walk-ins are listed, weekdays 8:00 a.m. to 12:00 p.m. and 1:00 p.m. to 4:30 p.m., last walk-in at 3:00 p.m.	(770) 520-7500
Adamsville Regional Health Center (Fulton County Board of Health), 3700 MLK Jr. Drive S.W.	STI screening and treatment on a sliding fee scale. The Board of Health says appointments are recommended.	(770) 520-7323
Neighborhood Union Health Center (Fulton County Board of Health), 186 Sunset Avenue N.W.	STI screening and treatment on a sliding fee scale. Its own pages list different days, so confirm hours by phone.	(770) 520-7351
AID Atlanta Wellness Center, 1438 W Peachtree Street NW	Free screening for chlamydia, gonorrhea and syphilis, free HIV testing, and free treatment for reactive screening results. Testing is listed Monday to Friday, 9:30 a.m. to 5:30 p.m.	(404) 870-7741
Planned Parenthood East Atlanta Health Center, 440 Moreland Avenue SE	STD testing and treatment. Insurance is not required. The health center accepts self-pay, and its page does not list a sliding scale.	404-688-9300

When you call, you could ask:

Do you offer M. genitalium testing, or can you refer me to a place that does?
Can the lab test for antibiotic resistance if the result is positive?
What does the visit cost, and do you offer a sliding scale?
Do I need an appointment, or can I walk in?

The Fulton County Board of Health's sexual health page is a good place to check current services. The AID Atlanta page lists the screenings it offers for free. Neither page names M. genitalium testing, so the answer has to come from the clinic.

How to judge a testing option

This stands in for "sourcing and quality." Here are indicators that a testing option is a sound one.

It is run by a clinic or health department. Fulton County Board of Health, DeKalb Public Health and established community clinics are accountable to public health standards.
A clinician is available. Results are only useful if someone can explain them and prescribe treatment if needed.
It states what it tests for. A clear list of infections beats a vague "full panel" claim.
It can say whether M. genitalium testing is included. If it cannot, ask for a referral.
It is open about cost. Fulton County Board of Health pages describe a sliding fee scale for people without insurance.

If you are under 18

The Fulton County Board of Health Teen Health Clinic serves people aged 12 to 21 and offers STI examinations. It says fees are based on income and family size, and that no teen is turned away for inability to pay. The clinic is at Adamsville, 3700 MLK Jr. Drive S.W., phone 770-520-7323.

Georgia law (O.C.G.A. § 31-17-7) lets a minor consent to care for a venereal disease without a parent's permission. The statute defines that term as syphilis, gonorrhea and chancroid. The Guttmacher Institute summarizes Georgia as allowing minors to consent to STI testing and treatment, and notes that providers may tell a parent. Ask the clinic how it handles privacy.

Next steps

If your symptoms have lasted or returned after treatment, a visit is the right next step. Tell the clinician what treatment you had and when. That history helps them decide whether to look for M. genitalium.

To find other testing sites, the CDC runs a locator at gettested.cdc.gov. It lets you look up free and low-cost options by ZIP code.

M. genitalium is treatable, and you are not alone in asking about it. Getting a clear answer is a reasonable and responsible thing to do.

Mycoplasma Genitalium: What It Is and Where to Get Tested in Atlanta